Drug profile · INN
amifampridine
RUZURGI
amifampridine (RUZURGI) is a voltage-gated potassium channel blocker. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — amifampridine
- US status
- approved
- Class
- Nervous system (N07)
- Route
- ORAL
- Patents
- 0
- Programs
- 7
- Data quality
- 0.84
Quick answer
amifampridine (RUZURGI) is a voltage-gated potassium channel blocker. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Voltage-gated potassium channel blocker
Primary target: Voltage-gated potassium channel
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is amifampridine?
amifampridine (RUZURGI) is a voltage-gated potassium channel blocker. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for amifampridine?
RUZURGI is a marketed brand name for amifampridine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of amifampridine?
amifampridine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.